Allogeneic hemopoietic stem cell transplantation for patients with myelofibrosis / 中国实用内科杂志
Chinese Journal of Practical Internal Medicine
; (12): 139-142, 2019.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-815994
Responsible library:
WPRO
ABSTRACT
Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only therapy to cure myelofibrosis(MF) at present. This article gives a review on the following problems who needs allo-SCT, how to choose allo-SCT in the era of ruxolitinib, the role of Ruxolitinib in the transplantation, whether allo-SCT can cure MF, and how to improve the effect of allo-SCT to guide the allo-SCT, in order for MF patients in clinical work.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Practical Internal Medicine
Year:
2019
Document type:
Article